TIMI 11A TIMI 11A A Multicenter Trial of the A Multicenter Trial of the Safety and Tolerability of Two Safety and Tolerability of Two Doses of Enoxaparin in Doses of Enoxaparin in Patients With Unstable Angina Patients With Unstable Angina and Non-Q-Wave Myocardial and Non-Q-Wave Myocardial Infarction Infarction E Antman et al for the TIMI 11 A Investigators. JACC 1997:29: 1474
28
Embed
TIMI 11A A Multicenter Trial of the Safety and Tolerability of Two Doses of Enoxaparin in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
TIMI 11ATIMI 11AA Multicenter Trial of the Safety and A Multicenter Trial of the Safety and
Tolerability of Two Doses of Enoxaparin Tolerability of Two Doses of Enoxaparin
in Patients With Unstable Anginain Patients With Unstable Angina
and Non-Q-Wave Myocardial Infarction and Non-Q-Wave Myocardial Infarction
TIMI 11ATIMI 11AA Multicenter Trial of the Safety and A Multicenter Trial of the Safety and
Tolerability of Two Doses of Enoxaparin Tolerability of Two Doses of Enoxaparin
in Patients With Unstable Anginain Patients With Unstable Angina
and Non-Q-Wave Myocardial Infarction and Non-Q-Wave Myocardial Infarction
E Antman et al for the TIMI 11 A Investigators. JACC 1997:29: 1474
Probability of Cardiovascular EventsProbability of Cardiovascular EventsDeath / MI / Rec Isch req. RevascDeath / MI / Rec Isch req. Revasc
E Antman et al for the TIMI 11 A Investigators. JACC 1997:29: 1474
Steady-State Anti-Xa Levels in Patients with Steady-State Anti-Xa Levels in Patients with Unstable AnginaUnstable Angina
Ant
i-Xa
(IU
/ml)
Ant
i-Xa
(IU
/ml)
3rd dose 3rd dose Last Last dose dose
3rd dose 3rd dose Last Last dosedose
1.25 mg/kg1.25 mg/kg 1.0 mg/kg1.0 mg/kg
TroughTroughPeakPeak
00
0.40.4
0.80.8
1.21.2
1.61.6
0.50.5
11
0.60.6
1.11.1
0.60.6
1.51.5
0.80.8
1.61.6
E Antman et al for the TIMI 11 A Investigators. JACC 1997:29: 1474
p = 0.006
0.4%0.3%
5.8%5.6%
0
1
2
3
4
5
6
7
All Patients Rapid cTnT Neg
p = 0.001
Mor
tali
ty a
t 1
4 D
ays
(%)
<1.55 mg/dL
>=1.55 mg/dL
CRP Concentration
N = 437 N = 346
TIMI 11ARisk Stratification
Baseline C-reactive Protein and Mortality
Morrow et al. JACC 1998;31:1460-5
ConclusionsConclusionsAcute PhaseAcute Phase
• Enoxaparin 1.0 mg/kg SQ q 12 H associated with a low Enoxaparin 1.0 mg/kg SQ q 12 H associated with a low
rate of major hemorrhage comparable to historical rates rate of major hemorrhage comparable to historical rates
of heparin in similar cohortsof heparin in similar cohorts
Anti-Xa activityAnti-Xa activity
• Dose-related increaseDose-related increase
• No accumulation after multiple dosesNo accumulation after multiple doses
Cardiovascular event rates are comparable in both dose tiersCardiovascular event rates are comparable in both dose tiersE Antman et al for the TIMI 11 A Investigators. JACC 1997:29: 1474
TIMI 11BTIMI 11B
The Effectiveness and Safety of The Effectiveness and Safety of Subcutaneous Enoxaparin Subcutaneous Enoxaparin Compared to Intravenous Compared to Intravenous
Unfractionated Heparin for Patients Unfractionated Heparin for Patients Presenting with Unstable Angina or Presenting with Unstable Angina or
Non-Q-wave MI: An International Non-Q-wave MI: An International Double-blind, Randomized, Parallel Double-blind, Randomized, Parallel
Group, Multicenter StudyGroup, Multicenter StudyAntman et al, Circulation 1999 Oct 12;100(15):1593-601
Countries:Countries: N. AmericaN. America S. AmericaS. America EuropeEuropeCanadaCanada ArgentinaArgentina SpainSpainUSAUSA UruguayUruguay FranceFrance
Antman et al, Circulation 1999 Oct 12;100(15):1593-601
PrimaryPrimary
• To demonstrate that uninterrupted enoxaparin SQ To demonstrate that uninterrupted enoxaparin SQ over 43 days is superior to UFH IV (72 H) over 43 days is superior to UFH IV (72 H) followed by aspirin alonefollowed by aspirin alone
SecondarySecondary
• Cost-effectiveness comparison of the different Cost-effectiveness comparison of the different treatment armstreatment arms
ObjectivesObjectives
Antman et al, Circulation 1999 Oct 12;100(15):1593-601
• Rest unstable angina or NQMIRest unstable angina or NQMI
• ST deviation > 0.5 mm or positive ST deviation > 0.5 mm or positive
serum cardiac markersserum cardiac markers
Inclusion CriteriaInclusion Criteria
Antman et al, Circulation 1999 Oct 12;100(15):1593-601
• Physician planning revascularization within 24 hours Physician planning revascularization within 24 hours
• Angina related to an evolving Q-wave MI angina Angina related to an evolving Q-wave MI angina
precipitated by secondary causes precipitated by secondary causes
revascularization at study day 43revascularization at study day 43
Primary EndpointPrimary Endpoint - Safety - Safety• Major hemorrhage at study day 43Major hemorrhage at study day 43
– DeathDeath
– Transfusion of >2 units packed bloodTransfusion of >2 units packed blood
– > 3 gm/dL fall in hemoglobin> 3 gm/dL fall in hemoglobin
– Intracranial, retroperitoneal, or intraocular hemorrhageIntracranial, retroperitoneal, or intraocular hemorrhageAntman et al, Circulation 1999 Oct 12;100(15):1593-601
ENOXENOX Bolus 30 mg IVBolus 30 mg IV1.0 mg / kg Q12h1.0 mg / kg Q12h
Pt. with UA/NQMI Pt. with UA/NQMI << 24 h 24 h
Primary Endpoint:
UFH UFH >> 3 days 3 daysBolus 70 U / kgBolus 70 U / kg
INF 15 U / kg / hINF 15 U / kg / h
Major BleedingSerious AEs
ASAASA
aPTT 1.5-2.5 x aPTT 1.5-2.5 x controlcontrol
Hosp DC Hosp DC (or 8 days)(or 8 days)
TIMI 11BProtocol Design
Death, MI, Urgent Revascularization
Acute Phase Protocol
Antman et al, Circulation 1999 Oct 12;100(15):1593-601
22
44
66
88
1010
1212
1414
1616
1818
2020
00 22 44 66 88 1010 1212 1414
P=0.029RRR 15 %
UFHUFHENOXENOX 16.7 %16.7 %
14.2 %14.2 %%
Days
14.5 %14.5 %
12.4 %12.4 %
P=0.048RRR 15 %
TIMI 11BPrimary Results
Death/MI/Urgent Revascularization at 14 Days
E. Antman for The TIMI 11B Investigators Circulation 1999.
0
1
2
3
4
5
6
7
8
9
0 8 16 24 32 40 48 56 64 72
% P
ts
UFHUFHENOXENOX
5.2 %5.2 %
4.2 %4.2 % RRR 18%RRR 18%P=0.20P=0.20
7.3 %7.3 %
5.5 %5.5 %
RRR 24%RRR 24%P=0.02P=0.02
ESSENCEESSENCE
TIMI 11 BTIMI 11 B
Hours from Randomization
Efficacy ResultsDeath/MI/Urgent Revasc. Early Rx Phase
TIMI 11B
E. Antman for The TIMI 11B Investigators Circulation 1999.
Efficacy ResultsTIMI 11B
- ESSENCE Meta-Analysis- ESSENCE Meta-Analysis
OVERALL
ESSENCE
TIMI 11B
OVERALL
ESSENCE
TIMI 11B
OVERALL
ESSENCE
TIMI 11B
0.5 1 2
Day
8
14
43
0.6 0.7 0.8 0.9Odds RatioEnox Better UFH Better
OR % p
0.77(0.62-0.95)
23 0.02
0.79(0.65-0.96)
21 0.02
0.82(0.69-0.97)
18 0.02
N
7081
7081
7081
3910
3910
3910
3171
3171
3171
UFH(%)
Enox (%)
5.3 4.1
6.5 5.2
8.6 7.1
Death/MI
Antman E, Cohen M for The TIMI 11B & ESSENCE Investigators Circulation 1999.
Pt. with UA/NQMI < 24 h
Death, MI, Severe Rec Isch Requiring Urgent Revasc
Acute = Day 8UFH iv > 72 hUFH iv > 72 h
Major Bleeding Serious AEs
ASA
ENOX iv-b,scENOX iv-b,sc
Placebo scPlacebo sc ENOX scENOX sc Chronic = Day 43
TIMI 11BProtocol Design
Antman et al, Circulation 1999 Oct 12;100(15):1593-601
DaysDays
0
2
4
6
8
10
12
14
16
18
20
0 4 8 12 16 20 24 28 32 36 40 44
P=0.048P=0.048RRR 12 %RRR 12 %
UFHUFHENOXENOX
19.7 %19.7 %
17.3 %17.3 %
%%
TIMI 11BPrimary Results: Chronic Phase
Death/MI/Urgent Revascularization at 43 Days
E. Antman for The TIMI 11B Investigators Circulation 1999.
TIMI 11BEfficacy Results
Efficacy of Enoxaparin Stratified by Baseline Risk
0.5 1 2
High(N=593)
Inter(N=1645)
Low(N=1672)
UFH(%)
ENOX(%)
OR (95 CI)
Favors ENOX
Favors UFHO.R.
29.6 0.78 (0.55,1.13)24.8
20.5 17.9
15.0 14.1
0.85 (0.66,1.08)
0.94 (0.72,1.23)
22
15
6
%
P=0.079 trend
Day 43 Death/MI/UR at 43 DaysDeath/MI/UR at 43 Days
Holper E. AHA 1998
TIMI 11BEfficacy Results
Efficacy of Enoxaparin Stratified by Rx Strategy
6.17.1
0
2
4
6
8
10
UFH ENOX
%
8.8
7
0
2
4
6
8
10
UFH ENOX
7.6 7.9
0
2
4
6
8
10
UFH ENOX
Med Rx
Guzman ESC 1999
PCI CABG
OR (95 CI) 0.85 (0.62,1.16) 0.77 (0.45,1.31) 1.04 (0.55,1.95)